Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trialSeong‐Ho Koh, Kyu‐Yong Lee, Jae‐Hong Lee et al.|Alzheimer s Research & Therapy|2021Cited by 38
Lecanemab: Appropriate Use Recommendations by Korean Dementia AssociationKee Hyung Park, Seong Hye Choi, Geon Ha Kim et al.|Dementia and Neurocognitive Disorders|2024Cited by 32
Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in AsiaKee Hyung Park, SangYun Kim, YoungSoon Yang et al.|Journal of Clinical Neurology|2021Cited by 12
Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: <i>Post Hoc</i> Analysis of Severe Impairment Battery SubscalesHyuk Sung Kwon, Sangjae Kim, Seong‐Ho Koh et al.|Dementia and Neurocognitive Disorders|2023Cited by 4